Home Tags Adcetris

Tag: Adcetris

Antibody-drug Conjugates: Technologies and Global Markets

Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new.  Due to many technological advances, recognition of appropriate target antigens, success...

Positive Results from Phase III ECHELON-1 Trial Evaluating Brentuximab Vedotin in...

ECHELON-1, a randomized, multicenter, phase III clinical trial evaluating brentiximab vedotin (Adcetris®) as part of a combination chemotherapy regimen in 1,334 patients with advanced...

Seattle Genetics Submits Supplemental Biologics License Application Brentuximab Vedotin in Cutaneous...

Seattle Genetics has submitted a supplemental Biologics License Application or BLA to the U.S. Food and Drug Administration (FDA) for brentuximab vedotin (Adcetris®) for...
Featured Image: Boston Public Garden; Boston, MA. Courtesy: © 2017 Fotolia. Used with permission.

PEGS Boston 2017: Catalent Biologics Advances Antibody-Drug Conjugate Development

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that...

AACR 2017: Advancing Antibody-Drug Conjugate and Novel Immuno-Oncology

Multiple data presentations supporting Seattle Genetics' advancing antibody-drug conjugate or ADC and immuno-oncology programs were presented at the Annual Meeting of the American Association...

Combination of Brentuximab Vedotin + Nivolumab Shows 90% Objective Response Rate...

The first reported data from an ongoing phase I/II clinical trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics)  in combination with nivolumab (Opdivo; Bristol-Myers Squibb...
Guell park in Barcelona

Anna Sureda MD PhD: “An Intelligent Way to Deliver High Doses...

Surrounded by fantastical and modernist landmarks designed by Antoni Gaudí, Barcelona, in the northeast of Spain, is a surreal wonderland where mansions look like...

Breakthrough Therapy Designation for Brentuximab Vedotin in CD30-expressing Mycosis Fungoides and...

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for brentuximab vedotin (Adcetris®; Seattle Genetics) for the treatment of patients with...

Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin lymphoma: Study...

The final data of the brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda Oncology) monotherapy pivotal phase II clinical trial in relapsed or refractory (R/R) classical Hodgkin...

Clinical Updates Confirming Advances and Meaningful Benefits for Patients

Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New Orleans, LA, and the Protein...